
SOPH Stock Forecast & Price Target
SOPH Analyst Ratings
Bulls say
Sophia Genetics is poised for continued growth with their innovative, data-driven medicine platform and strong presence in the US market. With top-performing applications in heme, solid tumor, and rare disease, a healthy backlog of revenue and plans for expanding their customer base, SOPH is expected to reach positive adjusted EBITDA in 2027. The company's estimated price target of $8, based on a multiple of 6.3x on their projected 2027 revenue of $109M, could potentially see upside with new customer wins and potential large pharma deals.
Bears say
Sophia Genetics is heavily reliant on deals with biopharma companies, like the recently renewed multi-year extension with AstraZeneca, and while there is potential for future extensions, the terms and size of these deals are not disclosed. Their pipeline is growing, but with only 70 customers signed to date and a decline in revenue per analysis, it is uncertain if this will translate into significant revenue growth. Additionally, profitability is not guaranteed in the medium term, making SOPH a risky investment option.
This aggregate rating is based on analysts' research of Sophia Genetics SA and is not a guaranteed prediction by Public.com or investment advice.
SOPH Analyst Forecast & Price Prediction
Start investing in SOPH
Order type
Buy in
Order amount
Est. shares
0 shares